UroGen Pharma to Present at Upcoming Investor Conferences
PRINCETON, N.J., Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- UroGen Pharma Ltd. ( Nasdaq: URGN ) , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor ...
Urogen Pharma ( URGN ) Reports Q2 Loss, Lags Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of -28.05% and -0.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
LENZ Therapeutics, Inc. ( LENZ ) Reports Q2 Loss
LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of +8.62% and 0.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025
Conference Call and Webcast Scheduled for Thursday, August 7th, 2025, at 10:00 AM ET ...
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025 - UroGen Pharma ( NASDAQ:URGN )
Conference Call and Webcast Scheduled for Thursday, August 7th, 2025, at 10:00 AM ET PRINCETON, N.J., July 29, 2025 ( GLOBE NEWSWIRE ) -- UroGen Pharma Ltd.
UROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma ( URGN ) Investors of the July 28th Deadline and Urges Investors in to Inquire About Their Rights in Class Action Lawsuit - UroGen Pharma ( NASDAQ:URGN )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma ( URGN ) To Contact Him Directly To Discuss Their Options
UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma ( URGN ) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit - UroGen Pharma ( NASDAQ:URGN )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma ( URGN ) To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of July 28, 2025 Lead Plaintiff Deadline in the UroGen Pharma Ltd. ( URGN ) Class Action - Investors With Significant Losses Encouraged to Contact the Firm - UroGen Pharma ( NASDAQ:URGN )
ATLANTA, July 21, 2025 ( GLOBE NEWSWIRE ) -- A shareholder class action lawsuit has been filed against UroGen Pharma Ltd. ( "UroGen" or the "Company" ) URGN. The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse ...
UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
PRINCETON, N.J., July 21, 2025 ( GLOBE NEWSWIRE ) -- UroGen Pharma Ltd. ( Nasdaq: URGN ) , a biotech company dedicated to developing and commercializing innovative solutions for urothelial and specialty cancers, today announced the publication of results of a five-year long-term extension study ...
UROGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors in UroGen Pharma ( URGN ) to Inquire About Their Rights in Class Action Lawsuit - UroGen Pharma ( NASDAQ:URGN )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma ( URGN ) To Contact Him Directly To Discuss Their Options
URGN Class Action News: UroGen Pharma Ltd. Investors with Large Losses Should Contact Robbins LLP Before July 28 for Information About Leading the Class Action - UroGen Pharma ( NASDAQ:URGN )
SAN DIEGO, July 17, 2025 ( GLOBE NEWSWIRE ) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. URGN securities between July 27, 2023 and May 15, 2025.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Organon, UroGen and Fortrea and Encourages Investors to Contact the Firm - Fortrea Holdings ( NASDAQ:FTRE ) , Organon ( NYSE:OGN )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Organon ( OGN ) , UroGen ( URGN ) , Red Cat ( RCAT ) , or Fortrea ( FTRE ) To Contact Him Directly To Discuss Their Options
Lowey Dannenberg Notifies UroGen Pharma Ltd. ( "UroGen" or the "Company" ) ( NASDQ: URGN ) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
NEW YORK, July 11, 2025 ( GLOBE NEWSWIRE ) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against UroGen Pharma Ltd. ( "UroGen" or the "Company" ) URGN for violations of the federal securities laws ...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm - Fortrea Holdings ( NASDAQ:FTRE ) , Reckitt Benckiser Group ( OTC:RBGLY )
NEW YORK, July 07, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reckitt Benckiser Group plc RBGLY, UroGen Pharma Ltd. URGN, Red Cat Holdings, Inc.
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
PRINCETON, N.J., July 07, 2025 ( GLOBE NEWSWIRE ) -- UroGen Pharma Ltd. ( Nasdaq: URGN ) , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has completed patient enrollment in its Phase 3 ...
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - UroGen Pharma ( NASDAQ:URGN )
PRINCETON, N.J., July 07, 2025 ( GLOBE NEWSWIRE ) -- UroGen Pharma Ltd.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN - UroGen Pharma ( NASDAQ:URGN )
NEW YORK, July 01, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. ( "UroGen" or the "Company" ) URGN. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ( or 888.4-POMLAW ) , ...
URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff Deadline in the URGN Class Action - Contact Robbins LLP Before July 28 for Information - UroGen Pharma ( NASDAQ:URGN )
SAN DIEGO, June 30, 2025 ( GLOBE NEWSWIRE ) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. URGN securities between July 27, 2023 and May 15, 2025.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm - Fortrea Holdings ( NASDAQ:FTRE ) , Reckitt Benckiser Group ( OTC:RBGLY )
NEW YORK, June 23, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reckitt Benckiser Group plc RBGLY, UroGen Pharma Ltd. URGN, Red Cat Holdings, Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN - UroGen Pharma ( NASDAQ:URGN )
NEW YORK, June 23, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ( "UroGen" or the "Company" ) URGN. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Lowey Dannenberg Notifies UroGen Pharma Ltd. ( "UroGen" or the "Company" ) ( NASDQ: URGN ) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
NEW YORK, June 23, 2025 ( GLOBE NEWSWIRE ) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against UroGen Pharma Ltd. ( "UroGen" or the "Company" ) URGN for violations of the federal securities laws ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN - UroGen Pharma ( NASDAQ:URGN )
NEW YORK, June 18, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ( "UroGen" or the "Company" ) URGN. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm - Fortrea Holdings ( NASDAQ:FTRE ) , Reckitt Benckiser Group ( OTC:RBGLY )
NEW YORK, June 16, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reckitt Benckiser Group plc RBGLY, UroGen Pharma Ltd. URGN, Red Cat Holdings, Inc.
Investors who lost money on UroGen Pharma Ltd. ( URGN ) should contact Levi & Korsinsky about pending Class Action - URGN - UroGen Pharma ( NASDAQ:URGN )
NEW YORK, June 16, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in UroGen Pharma Ltd. ( "UroGen Pharma Ltd." or the "Company" ) URGN of a class action securities lawsuit.
Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday - Advanced Micro Devices ( NASDAQ:AMD ) , AIRO Group Holdings ( NASDAQ:AIRO )
U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Monday. Shares of Sage Therapeutics, Inc. SAGE rose sharply during Monday's session after Supernus Pharmaceuticals agreed to acquire the company.
URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for Fraud - Investors with Losses are Notified to Contact BFA Law by July 28 Court Deadline ( NASDAQ:URGN ) - UroGen Pharma ( NASDAQ:URGN )
NEW YORK, June 16, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. URGN and certain of the Company's senior executives for potential violations of the federal securities laws.
URGN SHAREHOLDERS: UroGen Pharma Ltd. Investors are Reminded of the Pending Securities Fraud Class Action - Contact BFA Law by July 28 Deadline ( NASDAQ:URGN ) - UroGen Pharma ( NASDAQ:URGN )
NEW YORK, June 14, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. URGN and certain of the Company's senior executives for potential violations of the federal securities laws.
Why UroGen Pharma ( URGN ) Stock Is Skyrocketing This Week - UroGen Pharma ( NASDAQ:URGN )
UroGen Pharma shares are surging this week after the company gained FDA approval for ZUSDURI. The positive clinical trial results and an analyst upgrade fueled a significant stock price increase. Historic Summer Setup: 3 "Power Patterns" Triggering in the next 75 Days - Get The Details Now
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 28, 2025 in UroGen Pharma Ltd. Lawsuit - URGN - UroGen Pharma ( NASDAQ:URGN )
NEW YORK, June 13, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in UroGen Pharma Ltd. ( "UroGen Pharma Ltd." or the "Company" ) URGN of a class action securities lawsuit.
DEADLINE ALERT for DV, OGN, RCAT, and URGN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - DoubleVerify Holdings ( NYSE:DV ) , Organon ( NYSE:OGN )
LOS ANGELES, June 13, 2025 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Why Is UroGen Pharma Stock Trading Higher On Friday? - UroGen Pharma ( NASDAQ:URGN )
Zusduri showed a 78% complete response at 3 months in the Phase 3 ENVISION trial. 79% of 3-month responders remained event-free at 12 months. 3 Summer "Power Patterns" Are About to Trigger ( One With 90% Win Rate ) - Get The Details Now The U.S.
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday - Bunge Global ( NYSE:BG ) , AleAnna ( NASDAQ:ANNA )
U.S. stocks were lower, with the Dow Jones index falling around 600 points on Friday. Shares of Unusual Machines, Inc. UMAC rose sharply during Friday's session after the company agreed to acquire Rotor Lab in all-stock deal valued at $7 million.
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen - UroGen Pharma ( NASDAQ:URGN )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In UroGen To Contact Him Directly To Discuss Their Options
The Gross Law Firm Notifies UroGen Pharma Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline - URGN - UroGen Pharma ( NASDAQ:URGN )
NEW YORK, June 12, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of UroGen Pharma Ltd. URGN. Shareholders who purchased shares of URGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
DEADLINE ALERT for OGN, RCAT, URGN, FTRE: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - Fortrea Holdings ( NASDAQ:FTRE ) , Organon ( NYSE:OGN )
BENSALEM, Pa., June 12, 2025 ( GLOBE NEWSWIRE ) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
URGN CLASS ACTION: Invest in UroGen Pharma Ltd.? Contact BFA Law about the Pending Securities Fraud Class Action to Potentially Recover Losses ( NASDAQ:URGN ) - UroGen Pharma ( NASDAQ:URGN )
NEW YORK, June 12, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. URGN and certain of the Company's senior executives for potential violations of the federal securities laws.
Deadline Alert: UroGen Pharma Ltd. ( URGN ) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - UroGen Pharma ( NASDAQ:URGN )
LOS ANGELES, June 11, 2025 ( GLOBE NEWSWIRE ) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 28, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. ( "UroGen" or the ...
Contact Levi & Korsinsky by July 28, 2025 to Join Class Action Against UroGen Pharma Ltd. ( URGN )
Contact Levi & Korsinsky by July 28, 2025 to Join Class Action Against ...
Lowey Dannenberg Notifies UroGen Pharma Ltd. ( "UroGen" or the "Company" ) ( NASDQ: URGN ) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
NEW YORK, June 10, 2025 ( GLOBE NEWSWIRE ) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against UroGen Pharma Ltd. ( "UroGen" or the "Company" ) URGN for violations of the federal securities laws ...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against UroGen, Strategy Incorporated, and Organon and Encourages Investors to Contact the Firm - Strategy ( NASDAQ:MSTR ) , Organon ( NYSE:OGN )
NEW YORK, June 09, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of UroGen Pharma Ltd.
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 28, 2025 in UroGen Pharma Ltd. Lawsuit - URGN - UroGen Pharma ( NASDAQ:URGN )
NEW YORK, June 09, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of UroGen Pharma Ltd. URGN. Shareholders who purchased shares of URGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - URGN - UroGen Pharma ( NASDAQ:URGN )
NEW YORK, June 09, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of UroGen Pharma Ltd. URGN between July 27, 2023 and May 15, 2025, both dates inclusive ( the "Class ...
UROGEN PHARMA LTD. ( NASDAQ: URGN ) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds UroGen Pharma Ltd. Investors of Upcoming Deadline - UroGen Pharma ( NASDAQ:URGN )
NEW YORK, June 09, 2025 ( GLOBE NEWSWIRE ) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds UroGen Pharma Ltd. ( "UroGen" or the "Company" ) URGN investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Shareholders of UroGen Pharma Ltd. ( URGN ) : Protect Your Rights Before July 28, 2025 - Contact Levi & Korsinsky
Shareholders of UroGen Pharma Ltd. (URGN): Protect Your Rights Before July 28, 2025 - Contact Levi ...
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. ( URGN ) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - UroGen Pharma ( NASDAQ:URGN )
SAN DIEGO, June 09, 2025 ( GLOBE NEWSWIRE ) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UroGen Pharma Ltd. URGN securities between July 27, 2023 and May 15, 2025, all dates inclusive ( the "Class Period" ) , have until July 28, 2025 to seek appointment as lead ...
UroGen Pharma Ltd. ( URGN ) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before July 28, 2025
UroGen Pharma Ltd. (URGN) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before July ...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ...
Faruqi & Faruqi Reminds UroGen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 - URGN
Faruqi & Faruqi Reminds UroGen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July ...
URGN Investors with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against UroGen Pharma Ltd. - UroGen Pharma ( NASDAQ:URGN )
SAN DIEGO, June 06, 2025 ( GLOBE NEWSWIRE ) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. URGN securities between July 27, 2023 and May 15, 2025.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN - UroGen Pharma ( NASDAQ:URGN )
NEW YORK, June 06, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. ( "UroGen" or the "Company" ) URGN. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ( or 888.4-POMLAW ) , ...
